- Home
- NOM vs CGTX Comparison
NOM vs CGTX Comparison
Compare NOM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- CGTX
- Stock Information
- Founded
- NOM 1993
- CGTX 2007
- Country
- NOM United States
- CGTX United States
- Employees
- NOM N/A
- CGTX N/A
- Industry
- NOM Investment Managers
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- CGTX Health Care
- Exchange
- NOM Nasdaq
- CGTX Nasdaq
- Market Cap
- NOM 28.0M
- CGTX 26.8M
- IPO Year
- NOM N/A
- CGTX 2021
- Fundamental
- Price
- NOM $10.42
- CGTX $0.39
- Analyst Decision
- NOM
- CGTX Strong Buy
- Analyst Count
- NOM 0
- CGTX 6
- Target Price
- NOM N/A
- CGTX $7.50
- AVG Volume (30 Days)
- NOM 6.9K
- CGTX 651.3K
- Earning Date
- NOM 01-01-0001
- CGTX 03-20-2025
- Dividend Yield
- NOM 3.39%
- CGTX N/A
- EPS Growth
- NOM N/A
- CGTX N/A
- EPS
- NOM N/A
- CGTX N/A
- Revenue
- NOM N/A
- CGTX N/A
- Revenue This Year
- NOM N/A
- CGTX N/A
- Revenue Next Year
- NOM N/A
- CGTX N/A
- P/E Ratio
- NOM N/A
- CGTX N/A
- Revenue Growth
- NOM N/A
- CGTX N/A
- 52 Week Low
- NOM $8.52
- CGTX $0.34
- 52 Week High
- NOM $10.48
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- NOM 40.66
- CGTX 36.41
- Support Level
- NOM $10.39
- CGTX $0.38
- Resistance Level
- NOM $10.59
- CGTX $0.44
- Average True Range (ATR)
- NOM 0.09
- CGTX 0.04
- MACD
- NOM 0.03
- CGTX 0.00
- Stochastic Oscillator
- NOM 51.46
- CGTX 6.56
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.